Thursday, Amgen shares surged 5% as advisers told the Food and Drug Administration to warn patients not to use the company's top-selling anemia drug for head and neck cancer, breast cancer or in any case where patients might be cured of their cancer by chemotherapy.

Link to Article

Forbes.com